[go: up one dir, main page]

WO2024177525A3 - Épitope provenant de la protéine n du sars-cov-2, antigène contenant l'épitope, utilisations de celui-ci et procédé de détection d'une maladie provoquée par un coronavirus - Google Patents

Épitope provenant de la protéine n du sars-cov-2, antigène contenant l'épitope, utilisations de celui-ci et procédé de détection d'une maladie provoquée par un coronavirus Download PDF

Info

Publication number
WO2024177525A3
WO2024177525A3 PCT/PL2024/050015 PL2024050015W WO2024177525A3 WO 2024177525 A3 WO2024177525 A3 WO 2024177525A3 PL 2024050015 W PL2024050015 W PL 2024050015W WO 2024177525 A3 WO2024177525 A3 WO 2024177525A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
cov
sars
coronavirus
disease caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2024/050015
Other languages
English (en)
Other versions
WO2024177525A2 (fr
Inventor
Agnieszka RAZIM
Andrzej Gamian
Sabina GÓRSKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instytut Immunologii I Terapii Pan
Original Assignee
Instytut Immunologii I Terapii Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii I Terapii Pan filed Critical Instytut Immunologii I Terapii Pan
Publication of WO2024177525A2 publication Critical patent/WO2024177525A2/fr
Publication of WO2024177525A3 publication Critical patent/WO2024177525A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des épitopes provenant de la protéine N du SARS-CoV-2, des antigènes vaccinaux spécifiques du SARS-CoV-2 contenant les épitopes utiles dans le traitement ou la prévention d'une maladie provoquée par le coronavirus ainsi qu'un procédé de détection d'une maladie provoquée par un coronavirus, en particulier la COVID-19, notamment avec une évolution aiguë.
PCT/PL2024/050015 2023-02-22 2024-02-22 Épitope provenant de la protéine n du sars-cov-2, antigène contenant l'épitope, utilisations de celui-ci et procédé de détection d'une maladie provoquée par un coronavirus Ceased WO2024177525A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.443854 2023-02-22
PL443854A PL443854A1 (pl) 2023-02-22 2023-02-22 Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa

Publications (2)

Publication Number Publication Date
WO2024177525A2 WO2024177525A2 (fr) 2024-08-29
WO2024177525A3 true WO2024177525A3 (fr) 2024-09-19

Family

ID=90880435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2024/050015 Ceased WO2024177525A2 (fr) 2023-02-22 2024-02-22 Épitope provenant de la protéine n du sars-cov-2, antigène contenant l'épitope, utilisations de celui-ci et procédé de détection d'une maladie provoquée par un coronavirus

Country Status (2)

Country Link
PL (1) PL443854A1 (fr)
WO (1) WO2024177525A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188969A2 (fr) * 2020-03-20 2021-09-23 Biontech Us Inc. Vaccins à coronavirus et procédés d'utilisation
WO2021216983A1 (fr) * 2020-04-24 2021-10-28 Quidel Corporation Dosages immunologiques pour la détection d'immunoglobulines contre sars cov-2 et procédés d'utilisation
CN113717258A (zh) * 2021-09-03 2021-11-30 郑州安图生物工程股份有限公司 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021188969A2 (fr) * 2020-03-20 2021-09-23 Biontech Us Inc. Vaccins à coronavirus et procédés d'utilisation
WO2021216983A1 (fr) * 2020-04-24 2021-10-28 Quidel Corporation Dosages immunologiques pour la détection d'immunoglobulines contre sars cov-2 et procédés d'utilisation
CN113717258A (zh) * 2021-09-03 2021-11-30 郑州安图生物工程股份有限公司 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PAVLO HOLENYA ET AL: "Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, vol. 51, no. 7, 7 May 2021 (2021-05-07), pages 1839 - 1849, XP071228804, ISSN: 0014-2980, DOI: 10.1002/EJI.202049101 *
VOSS COURTNEY ET AL: "Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern", JCI INSIGHT, vol. 6, no. 13, 8 July 2021 (2021-07-08), XP093197005, ISSN: 2379-3708, DOI: 10.1172/jci.insight.148855 *
WANG HONGYE ET AL: "SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution", ACS CENTRAL SCIENCE, vol. 6, no. 12, 23 December 2020 (2020-12-23), pages 2238 - 2249, XP055864645, ISSN: 2374-7943, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c00742> DOI: 10.1021/acscentsci.0c00742 *

Also Published As

Publication number Publication date
PL443854A1 (pl) 2024-08-26
WO2024177525A2 (fr) 2024-08-29

Similar Documents

Publication Publication Date Title
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn&#39;s disease using the ompc antigen
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE542829T1 (de) Impfstoff
NO20072253L (no) Forbedrede vaksiner
WO2006031795A3 (fr) Calicivirus felin hemorragique, vaccin contre le calicivirus et methode de prevention de l&#39;infection ou de la maladie a calicivirus
NO20071523L (no) Vaksiner
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
WO2016176624A3 (fr) Pestivirus porcin, vaccins et dosages
WO2006065553A3 (fr) Vaccins glycoconjugues contenant un peptidoglycane
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
DE60336978D1 (de) Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
NO20081909L (no) Bovint viralt diare virus (BVDV), samt BVDV-vaksine
WO2003000719A3 (fr) Produit antigenique manifestant plusieurs copies d&#39;un epitope d&#39;un polypeptide formant des depots implique dans des maladies a formation de plaques et procedes d&#39;utilisation correspondants
WO2024177525A3 (fr) Épitope provenant de la protéine n du sars-cov-2, antigène contenant l&#39;épitope, utilisations de celui-ci et procédé de détection d&#39;une maladie provoquée par un coronavirus
WO2010042760A3 (fr) Compositions, procédés et nécessaires permettant de renforcer l&#39;immunogénicité d&#39;antigènes pathogènes
EP1379556A4 (fr) Anticorps dirige contre pityrosporum ovale igy et son utilisation
WO2005016952A3 (fr) Immunogene polyvalent
WO2007108568A8 (fr) Épitope hn reconnu par un système immunitaire aviaire et virus de maladie de newcastle à variants antigéniques porteurs de modifications dans l&#39;épitope
WO2024026468A3 (fr) Méthodes et compositions concernant des peptides cycliques destinés à être utilisés avec des anticorps et des fragments d&#39;anticorps
EP1657248A3 (fr) Vaccin pour la prevention et le traitement de la rhinite atrophique progressive porcine
TW200607812A (en) Prevention, treament and detection of porcine progressive atrophic rhinitis
WO2008009088A3 (fr) Composition vaccinale et méthode d&#39;immunisation
HK1041490A1 (zh) 來自百日咳杆菌的iii型分泌系統抗原
WO2004083390A3 (fr) Calicivirus felin systemique virulent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024721787

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24721787

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024721787

Country of ref document: EP

Effective date: 20250922